Experiment research on inhibition of glioma with sTRAIL in vitro

Abstract We report that adenovirus mediated TNF-related apoptosis-inducing ligand (TRAIL) influenced the cell growth and cell cycle in the glioma cells in vitro. After being infected with the Ad-sTRAIL, U251 cell growth was inhibited. The expression of sTRAIL was detected using immunofluorescence. The higher rate of apoptosis was demonstrated using short-term microculture tetrazoliun (MTT) assay and flow cytometry. The rate of Ad-sTRAIL-inducing U251 cell apoptosis was increased depending on the dosage and the time. The apoptosis of G0/G1 and S phase cells was more significant than that of the control groups. The growth and proliferation of U251 cell line was inhibited after the infection of Ad-sTRAIL. It is dose- and time dependent.

[1]  Michael R. Green,et al.  A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. , 2013, International journal of radiation oncology, biology, physics.

[2]  Yufang Xu,et al.  Induction of G2/M phase arrest and apoptosis by potent antitumor APCA in human cervix carcinoma cells , 2011, Anti-cancer drugs.

[3]  M. Aghaei,et al.  Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway , 2011, Journal of Cancer Research and Clinical Oncology.

[4]  Qiaojun He,et al.  Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo. , 2011, Cancer letters.

[5]  Jian Chen,et al.  Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro , 2010, Tumor Biology.

[6]  K. Song,et al.  Possible Novel Therapy for Malignant Gliomas with Secretable Trimeric TRAIL , 2009, PloS one.

[7]  A. Ashkenazi,et al.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Kauffmann,et al.  Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation , 2006, Oncogene.

[9]  G. Screaton,et al.  Following a TRAIL: Update on a ligand and its five receptors , 2004, Cell Research.

[10]  D. Seol,et al.  The secretable form of trimeric TRAIL, a potent inducer of apoptosis. , 2004, Biochemical and biophysical research communications.

[11]  P. Pandolfi,et al.  Activation of Akt/Protein Kinase B Overcomes a G2/M Cell Cycle Checkpoint Induced by DNA Damage , 2002, Molecular and Cellular Biology.

[12]  R. Perez-soler,et al.  Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. , 2002, Molecular pharmacology.

[13]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[14]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[15]  A. Kauffmann,et al.  Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation , 2007, Oncogene.